IL142295A - Use of acetylcarnitine for the preparation of an anti-tumour medicament - Google Patents
Use of acetylcarnitine for the preparation of an anti-tumour medicamentInfo
- Publication number
- IL142295A IL142295A IL14229599A IL14229599A IL142295A IL 142295 A IL142295 A IL 142295A IL 14229599 A IL14229599 A IL 14229599A IL 14229599 A IL14229599 A IL 14229599A IL 142295 A IL142295 A IL 142295A
- Authority
- IL
- Israel
- Prior art keywords
- tumour
- day
- group
- animals
- cells
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229960001009 acetylcarnitine Drugs 0.000 title claims abstract description 11
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract 2
- 102000005157 Somatostatin Human genes 0.000 claims description 7
- 108010056088 Somatostatin Proteins 0.000 claims description 7
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 7
- 229960000553 somatostatin Drugs 0.000 claims description 7
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 241000700159 Rattus Species 0.000 description 20
- 238000011081 inoculation Methods 0.000 description 20
- 206010003445 Ascites Diseases 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 10
- 229960004528 vincristine Drugs 0.000 description 10
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 8
- 229960001904 epirubicin Drugs 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 210000003567 ascitic fluid Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 6
- 230000002113 chemopreventative effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 206010023825 Laryngeal cancer Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000005264 laryngeal carcinoma Diseases 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 210000005170 neoplastic cell Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012143 endoscopic resection Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- UUVPYTIBUIBXTJ-ZDUSSCGKSA-N (2s)-2-[[4-[(2,4-diaminopteridin-7-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2C(N)=NC(N)=NC2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 UUVPYTIBUIBXTJ-ZDUSSCGKSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002634 anti-blastic effect Effects 0.000 description 1
- 230000001708 anti-dyslipidemic effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 238000012602 chemosensitivity assay Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000009800 partial cystectomy Methods 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1998MI002090A IT1302289B1 (it) | 1998-09-30 | 1998-09-30 | Composizioni farmaceutiche ad attivita' antineoplastica |
| PCT/EP1999/007170 WO2000018385A2 (en) | 1998-09-30 | 1999-09-27 | Use of acylcarnitines as antitumour agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL142295A0 IL142295A0 (en) | 2002-03-10 |
| IL142295A true IL142295A (en) | 2004-08-31 |
Family
ID=11380776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14229599A IL142295A (en) | 1998-09-30 | 1999-09-27 | Use of acetylcarnitine for the preparation of an anti-tumour medicament |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6673839B1 (de) |
| EP (1) | EP1117393B1 (de) |
| JP (1) | JP2002525316A (de) |
| AT (1) | ATE358476T1 (de) |
| AU (1) | AU761357B2 (de) |
| CA (1) | CA2345724C (de) |
| DE (1) | DE69935724T2 (de) |
| DK (1) | DK1117393T3 (de) |
| ES (1) | ES2284267T3 (de) |
| IL (1) | IL142295A (de) |
| IS (1) | IS5902A (de) |
| IT (1) | IT1302289B1 (de) |
| NO (1) | NO20011578L (de) |
| NZ (1) | NZ510803A (de) |
| WO (1) | WO2000018385A2 (de) |
| ZA (1) | ZA200102545B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006347935A (ja) * | 2005-06-15 | 2006-12-28 | Masanori Ogata | 炎症性サイトカインの産生が関与する疾患の予防及び／又は治療のための医薬 |
| CA2681185C (en) * | 2007-03-21 | 2018-05-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance |
| MX2011005593A (es) * | 2008-12-01 | 2011-06-20 | Sigma Tau Ind Farmaceuti | Uso de alcanoil l-carnitina en combinacion con agentes quimioterapeuticos para el tratamiento de neoplasmas. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05339148A (ja) * | 1992-05-28 | 1993-12-21 | T Knight Albert | 血液脳関門を通過する物質 |
| US5504069A (en) * | 1993-02-11 | 1996-04-02 | Biomeasure, Inc. | Inhibition of trauma-induced tumor growth |
| IT1277898B1 (it) * | 1995-08-03 | 1997-11-12 | Mendes Srl | Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie |
| WO1997006788A1 (en) * | 1995-08-14 | 1997-02-27 | Janssen Pharmaceutica N.V. | Transdermal administration of vorozole |
| JPH11292787A (ja) | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
| IT1283951B1 (it) | 1996-03-15 | 1998-05-07 | Mendes Srl | Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di |
| PT1100589E (pt) * | 1998-07-30 | 2005-05-31 | Sigma Tau Ind Farmaceuti | Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena |
-
1998
- 1998-09-30 IT IT1998MI002090A patent/IT1302289B1/it active IP Right Grant
-
1999
- 1999-09-27 EP EP99947427A patent/EP1117393B1/de not_active Expired - Lifetime
- 1999-09-27 IL IL14229599A patent/IL142295A/en not_active IP Right Cessation
- 1999-09-27 JP JP2000571904A patent/JP2002525316A/ja active Pending
- 1999-09-27 AU AU60877/99A patent/AU761357B2/en not_active Ceased
- 1999-09-27 CA CA002345724A patent/CA2345724C/en not_active Expired - Fee Related
- 1999-09-27 WO PCT/EP1999/007170 patent/WO2000018385A2/en not_active Ceased
- 1999-09-27 ES ES99947427T patent/ES2284267T3/es not_active Expired - Lifetime
- 1999-09-27 DK DK99947427T patent/DK1117393T3/da active
- 1999-09-27 AT AT99947427T patent/ATE358476T1/de not_active IP Right Cessation
- 1999-09-27 NZ NZ510803A patent/NZ510803A/en not_active IP Right Cessation
- 1999-09-27 DE DE69935724T patent/DE69935724T2/de not_active Expired - Lifetime
- 1999-09-27 US US09/806,153 patent/US6673839B1/en not_active Expired - Fee Related
-
2001
- 2001-03-20 IS IS5902A patent/IS5902A/is unknown
- 2001-03-28 ZA ZA200102545A patent/ZA200102545B/en unknown
- 2001-03-28 NO NO20011578A patent/NO20011578L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20011578L (no) | 2001-05-30 |
| ATE358476T1 (de) | 2007-04-15 |
| DK1117393T3 (da) | 2007-08-06 |
| ZA200102545B (en) | 2001-09-28 |
| EP1117393B1 (de) | 2007-04-04 |
| ES2284267T3 (es) | 2007-11-01 |
| WO2000018385A2 (en) | 2000-04-06 |
| JP2002525316A (ja) | 2002-08-13 |
| ITMI982090A1 (it) | 2000-03-30 |
| IS5902A (is) | 2001-03-20 |
| NZ510803A (en) | 2003-08-29 |
| CA2345724C (en) | 2009-05-19 |
| US6673839B1 (en) | 2004-01-06 |
| WO2000018385A3 (en) | 2000-05-25 |
| CA2345724A1 (en) | 2000-04-06 |
| DE69935724T2 (de) | 2007-12-27 |
| AU6087799A (en) | 2000-04-17 |
| DE69935724D1 (en) | 2007-05-16 |
| AU761357B2 (en) | 2003-06-05 |
| NO20011578D0 (no) | 2001-03-28 |
| IL142295A0 (en) | 2002-03-10 |
| EP1117393A2 (de) | 2001-07-25 |
| IT1302289B1 (it) | 2000-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ripamonti et al. | In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells | |
| Xu et al. | Improvement of anticancer effect of berberine by salt formation modifications | |
| US20100113585A1 (en) | Compositions and methods for treating cancer | |
| Han et al. | 8-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549 cells | |
| KR20250167640A (ko) | 아즈부딘 및 화학요법제를 포함한 항종양 약학적 조성물 | |
| US6673839B1 (en) | Pharmaceutical compositions with antitumour activity | |
| KR101656834B1 (ko) | 콜포신 다로페이트를 포함하는 골 질환의 예방 또는 치료용 조성물 | |
| KR101131224B1 (ko) | 염주괴불주머니 유래 쿠마린계 화합물, 및 이를 함유하는 항암용 조성물 | |
| US6242483B1 (en) | Selectively cytotoxic acetogenin compounds | |
| US5955497A (en) | Bioactive acetogenins | |
| WO1998048789A1 (en) | Pharmaceutical compositions of arglabin and arglabin derivatives | |
| JP2016500649A (ja) | テアニン誘導体とカルボン酸クマリン誘導体との縮合生成物、その中間体、調製方法、及びその使用 | |
| US9060985B2 (en) | Use of rosmarinic acid and the derivatives thereof to treat ciguatera | |
| MXPA06006717A (es) | Agentes de combinacion de chp-gencitabina y su uso como agentes anti-tumorales, especialmente como agentes anti-metastatizacion. | |
| KR102305178B1 (ko) | 큰괭이밥 추출물을 포함하는 췌장암 예방 또는 치료용 조성물 | |
| CN119331026B (zh) | 一种具有瑞格列奈四价铂结构的衍生物及其制备方法和用途 | |
| US20110124741A1 (en) | Radiosensitizer compositions comprising schisandra chinensis(turcz.)baill and methods for use | |
| CN117820273B (zh) | 一种乌药烷型倍半萜寡聚体、及其制备方法和在制备抗白血病药物中的用途 | |
| JP2002516609A (ja) | クラムベスチジン化合物 | |
| KR100398317B1 (ko) | 녹차카테킨(ｇｔｃ)을 유효성분으로 하는 세포보호제 | |
| JP4025817B2 (ja) | 新規なフラバン化合物 | |
| KR101679604B1 (ko) | DX2 단백질과 p14/ARF 단백질 간의 결합을 억제하는 신규 화합물 및 상기 화합물을 유효성분으로 함유하는 암질환 치료 또는 예방용 약학조성물 | |
| WO2025244951A1 (en) | Anti-cancer derivatives of ovatodiolide and use thereof | |
| Singh et al. | Azulene‐Based Systems of Biological Significance | |
| CN114957055A (zh) | 天然含硫酰胺类化合物glycocramide A及其在制备抗肿瘤药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |